Sara Bueno Ortín is Associate Director of Global Procurement at Almirall, where she leads R&D Procurement with a focus on clinical development, outsourcing strategy, and vendor management.
She has extensive experience negotiating complex contracts with CROs, CDMOs, and central labs, optimizing cost models, and ensuring operational excellence across global clinical programs.
Sara plays a key role in defining sourcing strategies, managing strategic suppliers, and implementing digital procurement tools to enhance efficiency and compliance.
Dr. Jeffrey S. Humphrey is CMO at Voro Therapeutics based in San Diego. He is an accomplished physician-scientist and senior biotech executive with more than two decades of leadership in global oncology drug development, spanning small molecules, antibodies, ADCs, radiopharmaceuticals, and epigenetic therapies. Harvard-educated and trained at Case Western Reserve, Johns Hopkins, and the National Cancer Institute, he has led early and late-stage clinical programs, overseen 11 NDA/BLA/MAA filings with 10 approvals, guiding development of three first-in-class medicines to U.S. and EU approval during his tenure as CMO/CDO at Kyowa Kirin. His career includes key roles at Bayer, Pfizer, and Bristol Myers Squibb—where he contributed to major launches such as Nexavar, Yervoy, and Sprycel—as well as CMO positions at Constellation Pharmaceuticals, Magenta Therapeutics, and Lantheus Holdings. He served on the Board of Directors of Cyteir Therapeutics and co-founded an early-stage venture, Charged Bio. Widely published with 60 scientific papers, Dr. Humphrey is recognized for building high-performing development organizations, advancing complex programs through pivotal inflection points, and integrating scientific, regulatory, and commercial strategy to drive innovation in precision oncology and next-generation therapeutics.
Kamil Sitarz is Chief Operating Officer and Management Board Member at Ryvu Therapeutics, a European clinical-stage oncology company advancing a diversified pipeline of innovative therapies. He leads corporate strategy, enterprise governance, capital planning, and cross-functional clinical development execution across a diversified oncology portfolio.
He has been instrumental in transforming Ryvu into a multi-program clinical-stage organization, embedding disciplined portfolio governance and architecting development pathways designed to enhance execution predictability in complex, high-risk oncology settings. His leadership integrates clinical strategy with capital allocation discipline, ensuring alignment across scientific ambition, regulatory positioning, operational design, and financial planning to drive sustainable enterprise value.
Under his direction, Ryvu has built and scaled a robust clinical development organization capable of delivering international Phase I/II programs across challenging hematologic indications and multi-country site networks. He has also played a key role in establishing and governing strategic clinical collaborations with leading global oncology partners, strengthening Ryvu’s development footprint and reinforcing its credibility within the international biotech ecosystem.
With a PhD in Medical Genetics and an Executive MBA, Kamil combines scientific depth with enterprise-level strategic and operational leadership to advance innovation with rigor, accountability, and long-term growth orientation.
Karin Johansson is an Associate Director and Team Leader for Clinical Sample Management within Clinical Operations at Ribocure Pharmaceuticals. In this role, she leads the planning and execution of clinical sample strategies and oversees the scientific, operational, and regulatory aspects of sample analyses in clinical trials. She holds a Master’s degree in Pharmaceutical Bioscience from the University of Gothenburg and has extensive experience across the drug development continuum. Her background includes more than15 years of hands-on laboratory research in cardiovascular disease at AstraZeneca, as well as clinical trial operations and site-based work as a clinical research nurse at Sahlgrenska University Hospital. Karin brings a unique perspective that integrates scientific, operational, and patient-centered aspects of clinical research.
Translational oncology scientist and scientific strategy leader with over a decade of experience integrating cancer genomics, mechanistic cell modeling, and biological insight to support target discovery, biomarker development, and precision oncology decision frameworks. Proven track record in translating complex multi-omics and computational outputs into biologically actionable insights and guiding cross-disciplinary teams across discovery and translational research initiatives. Experienced in bridging computational, experimental, and clinical perspectives to advance oncology research and therapeutic innovation.
I am an established Healthcare AI leader with over 15 years of experience in academia and industry, specializing in the integration of data science into the drug discovery process to enhance patient outcomes through precision medicine. My leadership philosophy centers on empathy, which I consider essential for cultivating high-performing teams.
As VP of Product Innovation & Strategy at Turbine, I lead a team driving product vision and roadmap at the intersection of science, technology, and strategy to transform drug discovery and development. My role bridges long-term innovation with near-term delivery, shaping priorities, guiding products from concept to launch, and building partnerships across pharma, biotech, and academia. By combining Turbine’s Virtual Biology platform with lab-in-the-loop innovation, we aim to deliver solutions with meaningful scientific and commercial impact for patients.
In my previous role at AZ, I led a global data science team delivering innovation in multi-modal data integration and deep insights into disease and drug mechanisms, informing critical portfolio milestones and reducing data-to-decision timelines. We leveraged the power of GenerativeAI to amplify insights from structured data representations across the drug discovery and development journey. My team’s efforts ensured the back-translation of clinical insights into early discovery, informing target discovery and patient-selection hypotheses.
My work is supported by a robust record of publications and presentations in the field of Healthcare AI.I am an established Healthcare AI leader with over 15 years of experience in academia and industry, specializing in the integration of data science into the drug discovery process to enhance patient outcomes through precision medicine. My leadership philosophy centers on empathy, which I consider essential for cultivating high-performing teams. As VP of Product Innovation & Strategy at Turbine, I lead a team driving product vision and roadmap at the intersection of science, technology, and strategy to transform drug discovery and development. My role bridges long-term innovation with near-term delivery, shaping priorities, guiding products from concept to launch, and building partnerships across pharma, biotech, and academia. By combining Turbine’s Virtual Biology platform with lab-in-the-loop innovation, we aim to deliver solutions with meaningful scientific and commercial impact for patients. In my previous role at AZ, I led a global data science team delivering innovation in multi-modal data integration and deep insights into disease and drug mechanisms, informing critical portfolio milestones and reducing data-to-decision timelines. We leveraged the power of GenerativeAI to amplify insights from structured data representations across the drug discovery and development journey. My team’s efforts ensured the back-translation of clinical insights into early discovery, informing target discovery and patient-selection hypotheses. My work is supported by a robust record of publications and presentations in the field of Healthcare AI.
Robert is a Solutions & Marketing Consultant who works at the intersection of clinical technology and client requirements. With over 4 years’ experience at CRScube, he has acquired deep familiarity with the company’s eClinical platform and the day-to-day realities of study teams. Throughout his tenure at CRScube, he has supported its expansion into European and North American markets, created user training, and developed product offerings and positioning. He regularly takes part in webinars, leveraging his platform knowledge to translate complex topics into simple explanations. He recently presented on CRScube’s development approach to USDM standards.
Dr. Varsano has 20+ years of experience in clinical research and 15+ years in leadership and oversight. He managed clinical studies for numerous rare disease indications, providing support for five approved drugs/molecules. He recently provided Project Director portfolio leadership for six rare disease Phase I-IV trials, with three of them receiving marketing authorization, one of which was a first-in-class therapy for a rare hematology condition.
- 20+ years of clinical research experience with 15+ years in leadership and oversight
- Managed rare disease clinical studies supporting five approved drugs/molecules
- Provided Project Director leadership for Phase I-IV trials, including a first-in-class rare hematology therapy
